stockrow
Saturday 7 November 2026
Export IRD’s income statement to Excel — free account
Opus Genetics, Inc.
Opus Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.2 million, up 29.1% from fiscal 2024.
- Revenue
- −73.8%
- EPS
- +33.3%
- Free cash flow
- −16.4%
Quarter to June 2026, against a year earlier
4.17
0.16
+3.99%
Follow IRD
Alert me
Opus Genetics, Inc. (IRD) P/E ratio
Opus Genetics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 8.2× (July 2020) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 4.3× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 15 more quarters | Free account |
Against its own ten years
Low 0.0×
High 8.2×
Ten-year median
0.0×
Current reading's percentile
87
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| IRD Opus Genetics, Inc. | n/m |
| OBIO Orchestra BioMed Holdings, Inc. compare | n/m |
| AVIR Atea Pharmaceuticals, Inc. compare | n/m |
| MPLT MapLight Therapeutics, Inc. compare | n/m |
| AUTL Autolus Therapeutics PLC Sponsored ADR compare | n/m |
| PROK ProKidney Corp. compare | n/m |
| FENC Adherex Technologies Inc. compare | n/m |
| SRZN Surrozen, Inc. compare | n/m |
| AGMB AgomAb Therapeutics NV compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)